Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abuse Potential of Lasmiditan
NCT03286218Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2017
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of lasmiditan in migraine (5 arms), sponsored by Eli Lilly and Company. Primary endpoint: Maximal Effect Score (Emax) of Bipolar Drug Liking Visual Analog Scale (VAS) at 24 hours. Started Sep 2017; status: completed.
02
Drugs
lasmiditan
03
Conditions
migraine
Beyond the preview
Go deeper on NCT03286218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03286218.